2025年净利最高预亏2.9亿元，双鹭药业盘中跌停

Core Viewpoint - The company, Shuanglu Pharmaceutical, has experienced a significant decline in stock price, reaching a limit down of 10.04% to 6.9 CNY per share, following the release of its 2025 earnings forecast indicating a projected net profit loss of 200 million to 290 million CNY, representing a year-on-year decline of 170.03% to 291.54% [1] Group 1 - The company forecasts a net profit loss for 2025 between 200 million to 290 million CNY, marking a substantial increase in losses compared to the previous year [1] - Factors contributing to the profit decline include industry policy adjustments and increased market competition, leading to a decrease in product prices and a corresponding drop in gross sales margin by approximately 10% [1] - Non-recurring losses are expected to reduce net profit by about 200 million CNY, primarily due to losses from investment management and changes in the fair value of trading financial assets [1] Group 2 - The company has acknowledged investment losses in its financial management, which it is currently attempting to recover through various means [1] - To protect the interests of small and medium shareholders, the chairman, Xu Mingbo, has voluntarily committed to cover any irrecoverable losses from these investments once confirmed [1]